Polaryx Therapeutics Inc. (PLYX) shares tumbled Wednesday, erasing a chunk of Tuesday's dramatic rally that followed a significant clinical trial announcement.
The stock had closed Tuesday up 64.32% at $3.96 after the company revealed it selected a contract research organization for its SOTERIA Phase 2 basket trial. But Wednesday brought the reality check investors in volatile biotech stocks know all too well.
The trial will evaluate PLX-200, Polaryx's lead drug candidate, across multiple lysosomal storage disorders—a group of rare genetic conditions. This CRO selection represents a crucial step forward as the company gears up to launch the trial in the first half of 2026.
What Makes This Trial Notable
The SOTERIA trial will assess PLX-200's safety, tolerability, and clinical activity across four different lysosomal storage disorders. Polaryx already has FDA clearance in hand, having received a safe-to-proceed letter back in October 2025.
The trial design includes natural history data as a control arm for comparison against patients receiving PLX-200. The compound itself is an orally available drug derived from gemfibrozil. According to Polaryx, strong clinical results could potentially lead to conditional marketing authorization.
The Bigger Picture Remains Challenging
Tuesday's surge notwithstanding, Polaryx has dropped 88.69% over the past year. The stock sits far closer to its 52-week low of $2.20 than its 52-week high of $48.91—a painful reminder of how quickly biotech valuations can deflate.
PLYX Price Action: Polaryx Therapeutics shares were down 22.47% at $3.07 at the time of publication Wednesday.
